Abstract
Clinical investigations of lividomycin, a new aminoglycosidic antibiotic, were carried out with urinary tract infections caused by Pseudomonas aeruginosa.
1. The MIC of lividomycin against P.aeruginosa was between 6.25mcg/ml and 50mcg/ml.The concentration of lividomycin in urine was significantly high as compared with in blood.When lividomycin was administered intramuscularly, the peak of urine levels reached in 1 hour after the administration, which continued for 7 hours.
2. Nine patients with urinary tract infections caused by P.aeruginosa were injected intramuscularly with 1.0-2.0g daily of lividomycin.
Good response was seen in all cases of acute or chronic cystitis, and in 2 out of 3 cases with pyelitis or pyelonephritis. Bacteriologically, remarkable response was found in all cases.No side effects were observed.
